Edition:
India

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

15.15USD
10:25pm IST
Change (% chg)

$-0.67 (-4.24%)
Prev Close
$15.82
Open
$15.85
Day's High
$15.88
Day's Low
$15.10
Volume
74,394
Avg. Vol
234,146
52-wk High
$26.05
52-wk Low
$10.09

Latest Key Developments (Source: Significant Developments)

GlycoMimetics Announces NCI-Sponsored Pivotal Trial Of GMI-1271 In Older, Newly Diagnosed AML Patients Fit For Intensive Chemotherapy
Wednesday, 30 May 2018 

May 30 (Reuters) - GlycoMimetics Inc ::GLYCOMIMETICS ANNOUNCES NCI-SPONSORED PIVOTAL TRIAL OF GMI-1271 IN OLDER, NEWLY DIAGNOSED AML PATIENTS FIT FOR INTENSIVE CHEMOTHERAPY.GLYCOMIMETICS INC - UNDER TERMS OF CRADA, NCI MAY ALSO FUND ADDITIONAL RESEARCH.GLYCOMIMETICS INC - CO TO SUPPLY GMI-1271 AS WELL AS PROVIDE FINANCIAL SUPPORT TO AUGMENT DATA ANALYSIS AND MONITORING FOR PHASE 3 PROGRAM.GLYCOMIMETICS INC - ANNOUNCED THAT GENERIC NAME FOR GMI-1271 WILL BE UPROLESELAN.  Full Article

GlycoMimetics qtrly loss per share $‍0.24
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and third quarter 2017 results.Glycomimetics inc - ‍phase 3 clinical trial of rivipansel on track for completion in second half of 2018​.Glycomimetics inc qtrly loss per share $‍0.24​.Glycomimetics inc - ‍research and development expenses decreased slightly to $5.8 million for quarter ended september 30, 2017 as compared to $5.9 million​.  Full Article

GlycoMimetics reports qtrly loss per share of $0.41
Friday, 5 Aug 2016 

GlycoMimetics Inc : GlycoMimetics reports second quarter 2016 results . Qtrly loss per share $0.41 .Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33

* GLYCOMIMETICS INC - AS OF MARCH 31, 2018, GLYCOMIMETICS HAD CASH AND CASH EQUIVALENTS OF $242.6 MILLION AS COMPARED TO $123.9 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage: